(Q56552815)

2

0 references

Xiaodong Xiao

3

0 references

Arya Biragyn

4

0 references

Antony S Dimitrov

5

0 references

Christopher C Broder

6

0 references

Dimiter S Dimitrov

Expert Opinion on Biological Therapy

7

0 references

language of work or name

English

0 references

publication date

March 2009

0 references

published in

0 references

volume

9

0 references

issue

3

0 references

page(s)

355-68

0 references

cites work

Virus entry: molecular mechanisms and biomedical applications

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Passive antibody therapy for infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Passive antibody therapies: progress and continuing challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Serum therapy revisited: animal models of infection and development of passive antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Preventing infectious disease with passive immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Antibodies for the prevention and treatment of viral diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Antiviral immunotherapy: a review of current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Successful Intravenous Immunoglobulin Therapy in 3 Cases of Parvovirus B19–Associated Chronic Fatigue Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Treatment of human enterovirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Intravenous immunoglobulins suppress the recurrences of genital herpes simplex virus: a clinical and immunological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

In vivo selection of respiratory syncytial viruses resistant to palivizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

A novel coronavirus associated with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Coronavirus as a possible cause of severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

SARS-Associated Coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

SARS corona virus peptides recognized by antibodies in the sera of convalescent cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Immunogenicity of SARS inactivated vaccine in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Susceptibility of pigs and chickens to SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Effects of a SARS-associated coronavirus vaccine in monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

The SARS-CoV S glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Risk factors for Nipah virus infection among abattoir workers in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Clinical features of Nipah virus encephalitis among pig farmers in Malaysia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Nipah virus: a recently emergent deadly paramyxovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Hendra and Nipah viruses: different and dangerous

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Developments towards effective treatments for Nipah and Hendra virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Nipah virus: vaccination and passive protection studies in a hamster model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Antibody prophylaxis and therapy against Nipah virus infection in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

The SARS-CoV S glycoprotein: expression and functional characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

21 January 2018

SARS vaccine development

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

A human SARS-CoV neutralizing antibody against epitope on S2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Bats are natural reservoirs of SARS-like coronaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Host cell recognition by the henipaviruses: Crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Structural definition of a conserved neutralization epitope on HIV-1 gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902763755

EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

Treating severe acute respiratory syndrome with hyperimmune globulins

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

Treatment of severe acute respiratory syndrome with convalescent plasma.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

Treatment of West Nile Virus Encephalitis with Intravenous Immunoglobulin

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

Introduction to Current focus on Hendra and Nipah viruses

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

High mortality in Nipah encephalitis is associated with presence of virus in cerebrospinal fluid

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

Nipah viral encephalitis or Japanese encephalitis? MR findings in a new zoonotic disease.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

The neurological manifestations of Nipah virus encephalitis, a novel paramyxovirus

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

Update: outbreak of Nipah virus--Malaysia and Singapore, 1999.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

Development and study of properties of immunoglobulins against Lassa fever

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

Intravenous immunoglobulin prophylaxis in an echovirus 6 and echovirus 4 nursery outbreak

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

A morbillivirus that caused fatal disease in horses and humans

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2705284

Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin--a report of eight patients

2 November 2018

1 reference

12 December 2020

Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection

1 reference

12 December 2020

Passive immunization for the prevention and treatment of HIV infection

1 reference

12 December 2020

Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines

1 reference

12 December 2020

Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy

1 reference

12 December 2020